HIV, HTLV AND DRUG ABUSE

HIV、HTLV 和药物滥用

• 批准号: 7349049
• 负责人: MARK A BEILKE
• 金额: $ 6.54万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349049
• 关键词: HIV; HTLV; DRUG; ABUSE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV/HTLV co-infections occur frequently and in the range of 1-15% among HIV-1 infected individuals. The relationship between levels of HTLV-1/2 viral burden and disease, and effects of antiretroviral treatment, however, is unknown. HTLV-1/2 ELISA-positive individuals (N=97) from the New Orleans, Louisiana, HIV Outpatient Clinic (HOP) were evaluated at baseline enrollment into a follow-up study. Variables considered were: demographics, use of street drugs, antiretroviral therapy, T cell subsets, HIV viral loads, HTLV-1/2 Western blotting, peripheral blood mononuclear cell (PBMC) cultures for detection of HTLV-1/2 p19 antigens, and real time PCR to quantify HTLV-1/2 proviral copy number. HTLV proviral load was dichotomized into ? 20,000 and 20,000 categories for ease of comparison. CD4 and CD8 were categorized into three ordinal categories, using well-established cut-points. Frequencies were computed and Chi-squared statistics or Fisher¿s Exact test were used to test for differences between groups. Hypothesis tests were two-sided and SAS version 8.2 was used to conduct statistical analysis. Among those subjects with a positive HTLV western blot confirmatory test, there was a statistically significant correlation between an HTLV-1/2 proviral copy number of 20,000 copies/106 PBMCs and a higher absolute CD4 cell count, HTLV-1 vs HTLV-2 western blot positivity, and a HTLV-1/2 p19 positive assay result. Preliminary data analysis suggested no differences with respect to race, gender, antiretroviral drug administration, or use of street drugs within the prior 3 months. These results suggest that HTLV-1/2 viral burden in PBMCs has an impact on disease staging among HIV-infected individuals.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。HIV/HTLV合并感染经常发生，在HIV-1感染者中的比例为1-15%。 然而，HTLV-1/2病毒负荷水平与疾病和抗逆转录病毒治疗效果之间的关系尚不清楚。对来自路易斯安那州新奥尔良市HIV门诊诊所（HOP）的HTLV-1/2 ELISA阳性个体（N=97）在基线入组时进行随访研究。考虑的变量为：人口统计学、街头药物的使用、抗逆转录病毒疗法、T细胞亚群、HIV病毒载量、HTLV-1/2蛋白质印迹、用于检测HTLV-1/2 p19抗原的外周血单核细胞（PBMC）培养物和定量HTLV-1/2前病毒拷贝数的真实的时间PCR。HTLV前病毒载量分为？20，000和20，000个类别以便于比较。使用明确的临界点，将CD 4和CD 8分为三个顺序类别。计算频率，并使用卡方统计或Fisher精确检验来检验组间差异。假设检验为双侧，使用SAS 8.2版进行统计分析。 在HTLV蛋白质印迹确证性试验阳性的受试者中，HTLV-1/2前病毒拷贝数20，000拷贝/106 PBMC与较高的绝对CD 4细胞计数、HTLV-1与HTLV-2蛋白质印迹阳性以及HTLV-1/2 p19阳性检测结果之间存在统计学显著相关性。初步数据分析表明，在种族，性别，抗逆转录病毒药物管理，或使用街头毒品在前3个月内没有差异。 这些结果表明，PBMC中的HTLV-1/2病毒负荷对HIV感染者的疾病分期有影响。